| 本文章共13655字，分2页，当前第2页，快速翻页： |
Altace(雷米普利，ramipril)
|
King Pharmaceuticals
|
2型糖尿病 (预防)
|
III期临床
|
|
Alveair(胰岛素吸入剂)
|
Coremed
|
糖尿病
|
I期临床
|
|
AMG 108
|
Amgen
|
糖尿病
|
II期临床
|
|
AMG 221
|
Amgen
|
2型糖尿病
|
I期临床
|
|
AMG 222
|
Amgen
|
2型糖尿病
|
II期临床
|
|
AMG 477
|
Amgen
|
2型糖尿病
|
I期临床
|
|
APD597
|
Arena Pharmaceuticals，Johnson & Johnson Pharmaceutical Research & Development
|
2型糖尿病
|
I期临床
|
|
Apidra SoloSTAR(格鲁辛胰岛素一次性注射笔)
|
Sanofi-Aventis
|
1型糖尿病
2型糖尿病
|
提交申请
|
|
AR9281
|
Arete Therapeutics
|
2型糖尿病
|
II期临床
|
|
ARI-2243
|
Arisaph Pharmaceuticals
|
2型糖尿病
|
I期临床
|
|
ARRY-403
|
Array BioPharma
|
2型糖尿病
|
I期临床
|
|
AT1391(胰岛素贴剂)
|
Altea Therapeutics
|
1型糖尿病
|
I/II期临床
|
|
2型糖尿病
|
I期临床
|
|
ATL-844
|
PGxHealth
|
2型糖尿病
|
II期临床
|
|
Avandamet XR
(罗格列酮/二甲双胍缓释制剂)
|
GlaxoSmithKline
|
2型糖尿病
|
III期临床
|
|
Avandia(罗格列酮)
|
GlaxoSmithKline
|
2型糖尿病 (预防)
|
III期临床
|
|
AVE0010(GLP1激动剂)
|
Sanofi-Aventis
|
2型糖尿病
|
III期临床
|
|
AVE0897(PPAR激动剂)
|
Sanofi-Aventis
|
2型糖尿病
|
I期临床
|
|
AVR 118
|
Advanced Viral Research
|
2型糖尿病
|
I期临床完成
|
|
AZD1656
|
AstraZeneca
|
2型糖尿病
|
II期临床
|
|
1型糖尿病
|
I期临床
|
|
AZD4017
|
AstraZeneca
|
2型糖尿病
|
I期临床
|
|
AZD6370
|
AstraZeneca
|
2型糖尿病
|
II期临床
|
|
balaglitazone
|
Dr. Reddy’s Laboratories
|
2型糖尿病
|
III期临床
|
|
basal insulin analog
(基础胰岛素类似物)
|
Eli Lilly
|
糖尿病
|
I期临床
|
|
BAY 73-7977
|
Bayer HealthCare Pharmaceuticals
|
糖尿病
|
I期临床
|
|
BGP15
|
N-Gene Research Laboratories
|
2型糖尿病
|
II期临床完成
|
|
BHT-3021
|
Bayhill Therapeutics，Juvenile Diabetes Research Foundation
|
1型糖尿病
|
I/II期临床
|
|
BI-10773
|
Boehringer Ingelheim Pharmaceuticals
|
2型糖尿病
|
II期临床
|
|
BI-44847
|
Boehringer Ingelheim Pharmaceuticals
|
2型糖尿病
|
II期临床
|
|
Byetta(exenatide)
|
Amylin Pharmaceuticals，
Eli Lilly
|
2型糖尿病 (单一药物治疗)
|
提交申请
|
|
2型糖尿病(青少年)
|
II期临床
|
|
canakinumab
|
Novartis Pharmaceuticals
|
2型糖尿病
|
II/III期临床
|
|
CCR2 拮抗剂
|
Bristol-Myers Squibb
|
糖尿病
|
临床研究中
<
|